Pierre Blanchard

List of Publications by Year in Descending Order

185 papers	5,882 citations	34 h-index	72 g-index
293 ext. papers	7,821 ext. citations	3.7 avg, IF	5.85 L-index

#	Paper	IF	Citations
185	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.. *Clinical and Translational Radiation Oncology*, **2022**, 32, 59-68	4.6	2
184	Anaplastic Thyroid Carcinoma: An Update.. *Cancers*, **2022**, 14,	6.6	3
183	Efficacy and toxicity following salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy.. *Brachytherapy*, **2022**,	2.4	1
182	Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives.. *Cancers*, **2022**, 14,	6.6	2
181	PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.. *Drugs*, **2022**, 1	12.1	0
180	The Post-Prostatectomy Setting: What to Do and When to Do? *International Journal of Radiation Oncology Biology Physics*, **2022**, 113, 254	4	
179	Best practice in brachytherapy.. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2021**, 26, 29-29	1.3	1
178	Twitter as a Medical Media Among French Young Oncologists: Results from a National Survey. *Journal of Cancer Education*, **2021**, 1	1.8	
177	Second malignancy (SM) in prostate cancer patients treated with SBRT and other contemporary radiation techniques. *Radiotherapy and Oncology*, **2021**, 164, 251-252	5.3	1
176	Penalized Poisson model for network meta-analysis of individual patient time-to-event data. *Statistics in Medicine*, **2021**, 41, 340	2.3	1
175	A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. *PLoS ONE*, **2021**, 16, e0259121	3.7	0
174	Pulsed Dose Rate Brachytherapy of Lip Carcinoma: Clinical Outcome and Quality of Life Analysis. *Cancers*, **2021**, 13,	6.6	2
173	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. *Advances in Radiation Oncology*, **2021**, 6, 100635	3.3	0
172	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. *Radiotherapy and Oncology*, **2021**, 156, 281-293	5.3	34
171	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. *Lancet Oncology, The*, **2021**, 22, 727-736	21.7	10
170	NTCP Modeling of Late Effects for Head and Neck Cancer: A Systematic Review. *International Journal of Particle Therapy*, **2021**, 8, 95-107	1.5	2
169	Methodologies to Increase the Level of Evidence of Real-life Proton Therapy in Head and Neck Tumors. *International Journal of Particle Therapy*, **2021**, 8, 328-338	1.5	2

168	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. *International Journal of Particle Therapy*, **2021**, 8, 374-382	1.5	1
167	Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a´non-endemic area. *Strahlentherapie Und Onkologie*, **2021**, 197, 188-197	4.3	3
166	Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection. *Laryngoscope*, **2021**, 131, E846-E850	3.6	1
165	Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. *Head and Neck*, **2021**, 43, 2325-2331	4.2	1
164	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. *Radiotherapy and Oncology*, **2021**, 160, 32-39	5.3	6
163	Carcinoma de nasofaringe. *EMC - Otorrinolaringología*, **2020**, 49, 1-9	0	
162	Cáncer de orofaringe. *EMC - Otorrinolaringología*, **2020**, 49, 1-18	0	
161	Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial. *Radiotherapy and Oncology*, **2020**, 150, 18-25	5.3	10
160	A biochemical definition of cure after brachytherapy for prostate cancer. *Radiotherapy and Oncology*, **2020**, 149, 64-69	5.3	17
159	Induction chemotherapy followed by radiotherapy for N3 head and neck squamous cell carcinoma. *Head and Neck*, **2020**, 42, 426-433	4.2	3
158	Response to R. Jayaraj. *Oral Oncology*, **2020**, 102, 104439	4.4	
157	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. *Radiotherapy and Oncology*, **2020**, 151, 314-321	5.3	14
156	Cancro della rofaringe. *EMC - Otorinolaringoiatria*, **2020**, 19, 1-17	0	
155	Carcinoma del rinofaringe. *EMC - Otorinolaringoiatria*, **2020**, 19, 1-8	0	
154	Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. *Advances in Radiation Oncology*, **2020**, 5, 111-119	3.3	3
153	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 618-627	4	107
152	Are Individual patient data meta-analyses still needed today in oncology? A discussion focused on Head and Neck oncology. *Acta Oncologica*, **2019**, 58, 1333-1336	3.2	2
151	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. *BJU International*, **2019**, 124, 35-39	5.6	2

150	Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma. *British Journal of Radiology*, **2019**, 92, 20190068	3.4	4
149	Nasopharyngeal carcinoma. *Lancet, The*, **2019**, 394, 64-80	40	747
148	Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas. *Systematic Reviews*, **2019**, 8, 96	3	4
147	Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. *Radiotherapy and Oncology*, **2019**, 136, 136-142	5.3	12
146	Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. *Current Oncology Reports*, **2019**, 21, 43	6.3	8
145	OC-010 Local recurrence of nasopharyngeal carcinomas outcomes after reirradiation. *Radiotherapy and Oncology*, **2019**, 132, 9-10	5.3	2
144	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. *Oral Oncology*, **2019**, 95, 106-114	4.4	11
143	Brachytherapy: An overview for clinicians. *Ca-A Cancer Journal for Clinicians*, **2019**, 69, 386-401	220.7	85
142	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. *Acta Oncologica*, **2019**, 58, 1378-1385	3.2	11
141	Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy. *Radiotherapy and Oncology*, **2019**, 130, 89-96	5.3	17
140	Proton versus photon radiation-induced cell death in head and neck cancer cells. *Head and Neck*, **2019**, 41, 46-55	4.2	16
139	Smoking and papillomavirus DNA in patients with p16-positive N3 oropharyngeal squamous cell carcinoma. *Head and Neck*, **2019**, 41, 1039-1045	4.2	2
138	Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer. *Oral Oncology*, **2019**, 88, 66-74	4.4	53
137	Prognostic factors in patients with soft palate squamous cell carcinoma. *Head and Neck*, **2019**, 41, 1441-1449	4.2	5
136	Re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. *European Urology*, **2019**, 75, e96-e97	10.2	1
135	Nedaplatin in nasopharyngeal cancer: the rebirth of platinum salts?. *Lancet Oncology, The*, **2018**, 19, 429-431	26.7	5
134	Lessons from the first 70 patients operated by doppler-guided haemorrhoidal artery ligation with mucopexy in a French team specialising in surgical proctology. *Journal of Coloproctology*, **2018**, 38, 111-116	0.5	2
133	Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study. *Brachytherapy*, **2018**, 17, 265-276	2.4	8

132	Anemia and neutrophil-to-lymphocyte ratio are prognostic in p16-positive oropharyngeal carcinoma treated with concurrent chemoradiation. *Papillomavirus Research (Amsterdam, Netherlands)*, **2018**, 5, 32-37	4.6	8
131	A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). *Annals of Oncology*, **2018**, 29, 731-736	10.3	91
130	Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma. *Brachytherapy*, **2018**, 17, 221-226	2.4	9
129	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 374-382	4	31
128	Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. *BJU International*, **2018**, 121, 540-548	5.6	19
127	Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy. *Clinical and Translational Radiation Oncology*, **2018**, 12, 8-15	4.6	9
126	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. *Seminars in Radiation Oncology*, **2018**, 28, 108-113	5.5	20
125	Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic. *Clinical and Translational Radiation Oncology*, **2018**, 12, 28-33	4.6	6
124	Smoking impact on HPV driven head and neck cancer's oncological outcomes?. *Oral Oncology*, **2018**, 82, 131-137	4.4	33
123	Long-term Outcome of a Fissurectomy: A Prospective Single-Arm Study of 50 Operations out of 349 Initial Patients. *Annals of Coloproctology*, **2018**, 34, 83-87	1.9	10
122	Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy. *Radiotherapy and Oncology* , **2018**, 126, 116-124	5.3	12
121	Proton Therapy for Head and Neck Cancers. *Seminars in Radiation Oncology*, **2018**, 28, 53-63	5.5	53
120	Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. *Radiotherapy and Oncology*, **2018**, 126, 107-115	5.3	77
119	Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?. *Clinical and Translational Radiation Oncology*, **2018**, 8, 4-11	4.6	110
118	In Regard to Sher et al. *Practical Radiation Oncology*, **2018**, 8, 66-67	2.8	
117	Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking?. *Journal of Clinical Oncology*, **2018**, 36, 2348-2349	2.2	2
116	Radiation-Related Alterations of Taste Function in Patients With Head and Neck Cancer: a Systematic Review. *Current Treatment Options in Oncology*, **2018**, 19, 72	5.4	35
115	Prevalence of burnout, depression and job satisfaction among French senior and resident radiation oncologists. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2018**, 22, 784-789	1.3	16

114	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. *Clinical and Translational Radiation Oncology*, **2018**, 13, 19-23	4.6	20
113	Pharmacological modulation of radiation-induced oral mucosal complications. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2018**, 22, 429-437	1.3	11
112	Prospective study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. *Clinical and Translational Radiation Oncology*, **2018**, 11, 11-18	4.6	12
111	Using Proton Beam Therapy in the Elderly Population: A Snapshot of Current Perception and Practice. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 840-842	4	4
110	Relationship between the time to locoregional recurrence and survival in laryngeal squamous-cell carcinoma. *European Archives of Oto-Rhino-Laryngology*, **2017**, 274, 2267-2271	3.5	5
109	Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy: Is Earlier Always Better?. *Journal of Clinical Oncology*, **2017**, 35, 1489-1490	2.2	4
108	Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 563-570	4	22
107	In Regard to Arthurs et´al. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 440	4	
106	What is the most effective treatment for head and neck squamous cell carcinoma? An individual patient data network meta-analysis from the MACH-NC and MARCH collaborative groups. *European Journal of Cancer*, **2017**, 72, S101-S102	7.5	2
105	Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. *Oral Oncology*, **2017**, 67, 138-145	4.4	17
104	Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage I-II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base. *Annals of Surgical Oncology*, **2017**, 24, 1419-1427	3.1	3
103	Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow. *Brachytherapy*, **2017**, 16, 734-742	2.4	20
102	Outcomes of multimodal management for sinonasal squamous cell carcinoma. *Journal of Cranio-Maxillo-Facial Surgery*, **2017**, 45, 1124-1132	3.6	28
101	Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. *Brachytherapy*, **2017**, 16, 761-769	2.4	7
100	SP-010: Update of the meta-analysis of chemotherapy in head and neck cancer (MACH-NC). *Radiotherapy and Oncology*, **2017**, 122, 9	5.3	5
99	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. *Radiotherapy and Oncology*, **2017**, 123, 401-405	5.3	43
98	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	31
97	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. *Cancer*, **2017**, 123, 1653-1661	6.4	44

96	Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. *Head and Neck*, **2017**, 39, 708-715	4.2	21
95	Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis. *European Archives of Oto-Rhino-Laryngology*, **2017**, 274, 1683-1690	3.5	27
94	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. *Journal of Clinical Oncology*, **2017**, 35, 498-505	2.2	176
93	ECOG-ACRIN 1308: Commentary on a Negative Phase II Trial. *Journal of Clinical Oncology*, **2017**, 35, 1969-1970	2.2	2
92	Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. *Journal of Gastrointestinal Oncology*, **2017**, 8, 173-179	2.8	8
91	Neutrophils, a candidate biomarker and target for radiation therapy?. *Acta Oncologica*, **2017**, 56, 1522-1530	3.2	31
90	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. *Radiotherapy and Oncology*, **2017**, 124, 232-239	5.3	38
89	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. *Lancet Oncology, The*, **2017**, 18, 1221-1237	21.7	156
88	Radiation Therapy is Independently Associated With Worse Survival After R0 Resection for Stage I-II Non-Small Cell Lung cancer: An Analysis of the National Cancer Data Base. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 230	4	3
87	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. *Brachytherapy*, **2017**, 16, 1021-1027	2.4	6
86	Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 590-595	4	8
85	Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?. *Current Opinion in Urology*, **2017**, 27, 580-586	2.8	2
84	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. *Clinical and Translational Radiation Oncology*, **2017**, 7, 28-35	4.6	12
83	Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. *OncoImmunology*, **2017**, 6, e1341030	7.2	22
82	Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status. *Oral Oncology*, **2017**, 71, 150-155	4.4	61
81	Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. *Laryngoscope*, **2017**, 127, 1791-1796	3.6	5
80	Incidence of small lymph node metastases in patients with nasopharyngeal carcinoma: Clinical implications for prognosis and treatment. *Head and Neck*, **2017**, 39, 305-310	4.2	6
79	Radiation-induced neurocognitive dysfunction in head and neck cancer patients. *Tumori*, **2017**, 103, 319-324	1.4	5

78	Intensity-Modulated Proton Therapy Adaptive Planning for Patients with Oropharyngeal Cancer. *International Journal of Particle Therapy*, **2017**, 4, 26-34	1.5	14
77	Sinonasal squamous cell carcinoma without clinical lymph node involvement : Which neck management is best?. *Strahlentherapie Und Onkologie*, **2016**, 192, 537-44	4.3	8
76	Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. *Radiotherapy and Oncology*, **2016**, 121, 395-401	5.3	142
75	Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?. *Oral Oncology*, **2016**, 59, 50-57	4.4	18
74	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. *European Journal of Cancer*, **2016**, 69, 151-157	7.5	21
73	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. *Oral Oncology*, **2016**, 62, 114-121	4.4	23
72	Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer. *Head and Neck*, **2016**, 38 Suppl 1, E905-10	4.2	7
71	Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery. *Head and Neck*, **2016**, 38 Suppl 1, E1722-9	4.2	6
70	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. *Medical Dosimetry*, **2016**, 41, 189-94	1.3	50
69	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 1107-14	4	88
68	Comment on "Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis", published in Eur J Cancer 51 (2015), 1570-1579. *European Journal of Cancer*, **2016**, 56, 183-185	7.5	5
67	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 360-367	4	61
66	Hypofractionation for prostate cancer: a word of caution. *Lancet Oncology, The*, **2016**, 17, 406-407	21.7	4
65	Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey. *European Archives of Oto-Rhino-Laryngology*, **2016**, 273, 2201-7	3.5	8
64	Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 85-92	4	19
63	Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. *Chinese Clinical Oncology*, **2016**, 5, 54	2.3	16
62	Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma. *Anticancer Research*, **2016**, 36, 6625-6630	2.3	9
61	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30. *European Urology*, **2016**, 70, e15-e16	10.2	4

60	Results and Survival of Locally Advanced AJCC 7th Edition T4a Laryngeal Squamous Cell Carcinoma Treated with Primary Total Laryngectomy and Postoperative Radiotherapy. *Annals of Surgical Oncology*, **2016**, 23, 2596-601	3.1	9
59	Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research. *Journal of Clinical Oncology*, **2016**, 34, 2317-8	2.2	7
58	Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. *Bone Marrow Transplantation*, **2016**, 51, 1076-81	4.4	15
57	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. *Radiotherapy and Oncology*, **2016**, 120, 48-55	5.3	129
56	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. *Radiotherapy and Oncology*, **2016**, 121, 381-386	5.3	60
55	MRI Simulation for LDR Prostate Brachyhtherapy: Can We Replace Ultrasound with MRI for Treatment Planning? Comparison of Pre-Planning, Day 0 and Day 30 MR Dosimetry. *Brachytherapy*, **2016**, 15, S57	2.4	2
54	Assessing head and neck cancer patient preferences and expectations: A systematic review. *Oral Oncology*, **2016**, 62, 44-53	4.4	26
53	OC-003: What is the best treatment in nasopharyngeal carcinoma? An individual patient data network meta-analysis. *Radiotherapy and Oncology*, **2015**, 114, 6-7	5.3	5
52	Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 202.e9-17	2.8	19
51	Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 108.e15-20	2.8	7
50	Méta-analyses d'essais randomisés sur données individuelles dans le traitement des cancers ORL non métastatiques : principes, résultats, perspectives. *Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique*, **2015**, 19, 228-229	1.3	
49	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *Lancet Oncology, The*, **2015**, 16, 645-55	21.7	453
48	(18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. *Oral Oncology*, **2015**, 51, 370-5	4.4	8
47	Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. *International Journal of Cancer*, **2015**, 136, 1494-503	7.5	155
46	Vocal fold mobility as the main prognostic factor of treatment outcomes and survival in stage II squamous cell carcinomas of the glottic larynx. *Journal of Laryngology and Otology*, **2015**, 129, 903-9	1.8	9
45	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. *Journal of Neuro-Oncology*, **2015**, 123, 307-14	4.8	13
44	Influence of the vocal cord mobility in salvage surgery after radiotherapy for early-stage squamous cell carcinoma of the glottic larynx. *European Archives of Oto-Rhino-Laryngology*, **2015**, 272, 3013-8	3.5	3
43	Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies. *Hematology/Oncology Clinics of North America*, **2015**, 29, 1107-22	3.1	35

42	In reply to Alber and Sün. *International Journal of Radiation Oncology Biology Physics*, **2015**, 91, 679	4	1
41	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. *European Journal of Dermatology*, **2014**, 24, 265-7	0.8	5
40	Reply to D. Tural et al. *Journal of Clinical Oncology*, **2014**, 32, 259-60	2.2	
39	Mobile technology and social media in the clinical practice of young radiation oncologists: results of a comprehensive nationwide cross-sectional study. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 231-7	4	19
38	Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. *Strahlentherapie Und Onkologie*, **2014**, 190, 823-31	4.3	37
37	Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?. *Strahlentherapie Und Onkologie*, **2014**, 190, 654-60	4.3	9
36	Functional data analysis in NTCP modeling: a new method to explore the radiation dose-volume effects. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 654-63	4	16
35	Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas. *Anti-Cancer Drugs*, **2014**, 25, 1220-6	2.4	4
34	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients.. *Journal of Clinical Oncology*, **2014**, 32, 6022-6022	2.2	3
33	Toxicities of tyrosine kinase inhibitors: Occurrence of hemoptysis and tracheo-oesophageal fistula in 150 patients with advanced thyroid cancer.. *Journal of Clinical Oncology*, **2014**, 32, 6077-6077	2.2	
32	A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse.. *Journal of Clinical Oncology*, **2014**, 32, TPS5098-TPS5098	2.2	1
31	Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma: in regard to Yang et al. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 811	4	4
30	Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. *Journal of Clinical Oncology*, **2013**, 31, 2854-60	2.2	187
29	Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma. *Oral Oncology*, **2013**, 49, 830-4	4.4	28
28	Who dies from prostate cancer in a Western country? A multicenter analysis.. *Journal of Clinical Oncology*, **2013**, 31, 211-211	2.2	1
27	Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. *Lancet Oncology, The*, **2012**, 13, 145-53	21.7	235
26	Absent benefit of accelerated concomitant chemoradiotherapy□Authors' reply. *Lancet Oncology, The*, **2012**, 13, e136-e137	21.7	2
25	Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1522-7	4	82

24	Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: Impact on survival. *Neuro-Oncology*, **2012**, 14, 1413-21	1	13
23	Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. *BMC Cancer*, **2012**, 12, 119	4.8	18
22	Horseshoe tract of anal fistula: bad luck or an avoidable extension? Lessons from 82 cases. *Colorectal Disease*, **2012**, 14, 1512-5	2.1	9
21	Definitive radiotherapy for squamous cell carcinoma of the pyriform sinus. *Radiotherapy and Oncology*, **2012**, 105, 232-7	5.3	11
20	Les internes et le burnout. *Oncologie*, **2012**, 14, 343-344	1	0
19	On the prevalence and causes of oncologist burnout. *Journal of Clinical Oncology*, **2012**, 30, 3029-30; author reply 3030	2.2	7
18	Personalizing treatment in patients with castrate-resistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity.. *Journal of Clinical Oncology*, **2012**, 30, 213-213	2.2	23
17	Relapses in metastatic germ-cell tumors and relationship to international guidelines compliance: A study from the Institut Gustave Roussy.. *Journal of Clinical Oncology*, **2012**, 30, 323-323	2.2	3
16	eLQ : A biologically-equivalent dose calculator available on iPhone, Android, and the web. *Practical Radiation Oncology*, **2011**, 1, 212-3	2.8	1
15	TAXANE-CISPLATIN-5FU AS INDUCTION CHEMOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF THE MACH-NC GROUP. *Radiotherapy and Oncology*, **2011**, 98, S6	5.3	6
14	Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. *Journal of Clinical Epidemiology*, **2011**, 64, 985-92	5.7	47
13	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. *Radiotherapy and Oncology*, **2011**, 100, 33-40	5.3	422
12	Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. *Radiotherapy and Oncology*, **2011**, 100, 56-61	5.3	16
11	Endorectal advancement flap with muscular plication: a modified technique for rectovaginal fistula repair. *Colorectal Disease*, **2011**, 13, 921-5	2.1	30
10	Syndrome d'épuisement professionnel des soignants. *Oncologie*, **2011**, 13, 845-863	1	6
9	Management et souffrance des soignants en oncohématologie. *Psycho-oncologie*, **2011**, 5, 83-91	0	11
8	Delineation in thoracic oncology: a prospective study of the effect of training on contour variability and dosimetric consequences. *Radiation Oncology*, **2011**, 6, 118	4.2	33
7	Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. *Journal of Clinical Oncology*, **2011**, 29, 2590-7	2.2	38

6	Low-dose-rate definitive brachytherapy for high-grade vaginal intraepithelial neoplasia. *Oncologist*, **2011**, 16, 182-8	5.7	17
5	Prevalence and causes of burnout amongst oncology residents: a comprehensive nationwide cross-sectional study. *European Journal of Cancer*, **2010**, 46, 2708-15	7.5	141
4	Prophylactic cranial irradiation in lung cancer. *Current Opinion in Oncology*, **2010**, 22, 94-101	4.2	17
3	Hyperfractionated or accelerated radiotherapy for head and neck cancer. *The Cochrane Library*, **2010**,	5.2	25
2	Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. *Gynecologic Oncology*, **2007**, 104, 41-5	4.9	39
1	Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. *Aids*, **2007**, 21, 187-92	3.5	101